» Articles » PMID: 12879326

The Relationship Between Cognitive Impairment and in Vivo Metabolite Ratios in Patients with Clinical Alzheimer's Disease and Vascular Dementia: a Proton Magnetic Resonance Spectroscopy Study

Overview
Journal Neuroradiology
Specialties Neurology
Radiology
Date 2003 Jul 25
PMID 12879326
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Previous magnetic resonance spectroscopy (MRS) studies have shown increased myo-inositol (MI) and decreased N-acetyl aspartate (NAA) levels in the parieto-occipital lobes of patients with Alzheimer's disease (AD) compared to those with other dementias and normal subjects. This study aimed to establish the quantitative relationship between metabolite ratios and degree of cognitive impairment in patients with mild to moderate AD and sub-cortical ischaemic vascular dementia (SIVD). Forty-four older people with clinical dementia were recruited from a memory clinic and followed up for 2.0-3.5 years; 20 cases were finally classified as probable AD, 18 as SIVD and 6 as mixed type. Mini Mental State Examination (MMSE) and short echo time single voxel automated MRS from the mesial parieto-occipital lobes were performed at the time of initial referral. Spearman rank correlation coefficients were calculated for MMSE scores and measured metabolite ratios MI/Cr, NAA/Cr, Cho/Cr and NAA/MI. The AD group showed a significant correlation between MMSE and NAA/MI (r=0.54, P=0.014) and NAA/Cr (r=0.48, P=0.033), and a negative, non-significant association with MI/Cr (r=-0.41, P=0.072). MI/Cr was negatively correlated with NAA/Cr (r=-0.51, P=0.021). Neither Cho/Cr ratios nor age correlated with cognitive function. The SIVD group showed no correlation between any of the measured metabolite ratios and MMSE score. This study reinforces the specific association between reduced NAA and increased MI levels in the parieto-occipital region and cognitive impairment in AD. MRS may have a role in evaluating disease progression and therapeutic monitoring in AD, as new treatments become available.

Citing Articles

Imaging Methods Applicable in the Diagnostics of Alzheimer's Disease, Considering the Involvement of Insulin Resistance.

Hnilicova P, Kantorova E, Sutovsky S, Grofik M, Zelenak K, Kurca E Int J Mol Sci. 2023; 24(4).

PMID: 36834741 PMC: 9958721. DOI: 10.3390/ijms24043325.


Brain neurometabolites differences in individuals with subjective cognitive decline plus: a quantitative single- and multi-voxel proton magnetic resonance spectroscopy study.

Yang Z, Wan X, Zhao X, Rong Y, Wu Y, Cao Z Quant Imaging Med Surg. 2021; 11(9):4074-4096.

PMID: 34476190 PMC: 8339653. DOI: 10.21037/qims-20-1254.


Mini-Mental State Examination and proton spectroscopy of the posterior cingulate in Alzheimer disease.

Lee H, Caramelli P, Garcia Otaduy M, Nitrini R, da Costa Leite C Dement Neuropsychol. 2017; 1(3):248-252.

PMID: 29213397 PMC: 5619002. DOI: 10.1590/S1980-57642008DN10300005.


Hydrogen Proton Magnetic Resonance Spectroscopy in Multidomain Amnestic Mild Cognitive Impairment and Vascular Cognitive Impairment Without Dementia.

Chen S, Cai Q, Shen Y, Xu C, Zhou H, Zhao Z Am J Alzheimers Dis Other Demen. 2016; 31(5):422-9.

PMID: 26980718 PMC: 10852783. DOI: 10.1177/1533317515628052.


Various MRS application tools for Alzheimer disease and mild cognitive impairment.

Gao F, Barker P AJNR Am J Neuroradiol. 2014; 35(6 Suppl):S4-11.

PMID: 24742809 PMC: 4401041. DOI: 10.3174/ajnr.A3944.


References
1.
Scahill R, Schott J, Stevens J, Rossor M, Fox N . Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci U S A. 2002; 99(7):4703-7. PMC: 123711. DOI: 10.1073/pnas.052587399. View

2.
Antuono P, Jones J, Wang Y, Li S . Decreased glutamate + glutamine in Alzheimer's disease detected in vivo with (1)H-MRS at 0.5 T. Neurology. 2001; 56(6):737-42. DOI: 10.1212/wnl.56.6.737. View

3.
Dixon R, Bradley K, Budge M, Styles P, Smith A . Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. Brain. 2002; 125(Pt 10):2332-41. DOI: 10.1093/brain/awf226. View

4.
Waldman A, Rai G, McConnell J, Chaudry M, Grant D . Clinical brain proton magnetic resonance spectroscopy for management of Alzheimer's and sub-cortical ischemic vascular dementia in older people. Arch Gerontol Geriatr. 2004; 35(2):137-42. DOI: 10.1016/s0167-4943(02)00014-6. View

5.
Adalsteinsson E, Sullivan E, Kleinhans N, Spielman D, Pfefferbaum A . Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet. 2000; 355(9216):1696-7. DOI: 10.1016/s0140-6736(00)02246-7. View